{"brief_title": "A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer", "brief_summary": "This study will assess the efficacy and safety of intermittent oral Xeloda administration in combination with irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the target sample size is <100 individuals.", "condition": ["Colorectal Cancer"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Irinotecan", "capecitabine [Xeloda]"], "description": ["250mg/m2 iv on day 1 of each 3 week cycle", "1000mg/m2 po bid on days 1-15 of each 3 week cycle"], "arm_group_label": ["1", "1"], "criteria": "Inclusion Criteria: - adult patients >=18 years of age; - locally advanced and/or metastatic colorectal cancer; - >=1 target lesion. Exclusion Criteria: - previous treatment with Xeloda or irinotecan; - previous systemic therapy for metastatic disease; - progressive disease during previous adjuvant therapy or within 6 months of completion.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Colorectal Neoplasms", "Capecitabine", "Irinotecan"], "id": "NCT00048139"}